Acumen Pharmaceuticals, Inc.ABOSNASDAQ
Loading
Free Cash Flow Growth Under PressureDecelerating
Percentile Rank59
5Y CAGR-21.4%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
-21.4%/yr
Long-term compound
Percentile
P59
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 4.25% |
| Q2 2025 | 6.90% |
| Q1 2025 | -25.67% |
| Q4 2024 | -10.65% |
| Q3 2024 | -48.62% |
| Q2 2024 | 7.39% |
| Q1 2024 | -114.58% |
| Q4 2023 | 35.50% |
| Q3 2023 | -10.64% |
| Q2 2023 | -14.69% |
| Q1 2023 | 9.46% |
| Q4 2022 | -21.31% |
| Q3 2022 | -42.44% |
| Q2 2022 | 21.71% |
| Q1 2022 | -126.68% |
| Q4 2021 | 52.38% |
| Q3 2021 | -80.23% |
| Q2 2021 | -80.17% |
| Q1 2021 | 17.05% |
| Q4 2020 | -122.68% |
| Q3 2020 | 14.12% |
| Q2 2020 | 17.73% |
| Q1 2020 | 0.00% |